Navigation Links
New drug development still takes 8 years despite faster FDA review, according to Tufts CSDD
Date:1/8/2009

BOSTON Jan. 8, 2009 While the U.S. Food and Drug Administration Drug has quickened review and approval of new medicines, the complex nature of diseases for which new therapeutics are being developed has resulted in longer clinical development times, according to the Tufts Center for the Study of Drug Development.

The average time for the FDA to approve new drugs declined to 1.1 years in the 2005-07 period, but longer average clinical phase time means combined clinical and approval time continues to hover around eight years, according to Tufts CSDD.

"Even though the total time to bring new drugs to market has remained essentially unchanged in recent years, drug developers are making progress," said Tufts CSDD Director Kenneth I Kaitin, who made his comments in connection with the release today of the Tufts Center's Outlook 2009 report on pharmaceutical and biopharmaceutical trends.

"Many factors are leading to longer clinical times, including a focus on complex diseases and more complicated development design protocols," he added.

Drug companies have taken steps to speed clinical development, according to Kaitin, including improving project management, expanding use of partnerships and licensing arrangements, and increasing use of surrogate endpoints and adaptive clinical trials.

"Still, in drug development, the raceand rewardsgo to the swiftest and most efficient drug sponsors, those that can deliver safe and effective new medicines in the shortest time," he said.

Among the near-term trends cited in the Tufts CSDD's Outlook 2009 report are the following:

  • Firms will continue globalization of their preclinical and clinical development activities to overcome local capacity constraints, increase speed-to-market, and expand their presence in emerging markets.

  • Continued shortages of experienced personnel, especially among upper level managerial staff, will continue to hamper the FDA
    '/>"/>

Contact: Charlene Neu
617-636-2187
Tufts University, Health Sciences
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Isolation of a new gene family essential for early development
2. Therap Services Continues to Hire Experienced Developmental Disability Industry Clinicians for its Customer Support Team
3. The Philadelphia Walk Now for Autism Expected to Draw 10,000 Walkers and Raise $1 Million to Help Find Answers About the Nations Fastest-Growing Developmental Disorder
4. Ovation further advances development pipeline with new phase III epilepsy study
5. Pioneer Surgical Technology Hires Vice President of New Business Development
6. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
7. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
8. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
9. Optim To Assist Prairie Community Health Center with Construction Scope Development
10. Nick Childs Joins Grey New York as Director of Content Development
11. New clues to breast cancer development in high-risk women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Aeroflow Healthcare, an industry leader and ... the opening of its new office to be located ... Business Parkway, Suite D, Greer, SC 29651. This new ... a more convenient location in the Greenville area. , ... the physicians, hospitals and patients we serve, to ensure ...
(Date:9/2/2014)... “Harmonicas have been formally used in ... help people with COPD or asthma. At this ... says Dana Keller, PhD, co-inventor of the Pulmonica. ... much the same – improved health with the ... , The three approaches to harmonicas in healthcare ...
(Date:9/2/2014)... During the fall season, before the ... winter months to prevent costly damage later on. Pasquali ... company, suggests these fall preventative home maintenance tips. , ... throughout fall to prevent build up of leaves and ... problems, pest infestations, wet basements, foundation damage and many ...
(Date:9/1/2014)... BambooIndustry.com is one of the most ... famous for its high quality and elegant floors, plywoods, ... its new range of solid bamboo floors ... company has confidence in the new collection. BambooIndustry.com is ... of elegant bamboo items and great customer services. Also, ...
(Date:9/1/2014)... Securityhunter has experienced rapid growth ... search for a new, larger headquarters. The newly ... the space of our office to 10,000 square feet. ... from glass topped cubicles with doors, to beautiful large conference ... warehouse," says Michael S. Rogers, CEO of Securityhunter. “Our ...
Breaking Medicine News(10 mins):Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Suggests These Maintenance Tips for Homeowners This Fall 2Health News:BambooIndustry.com: Solid Bamboo Floors Provided At Discounted Rates 2Health News:Securityhunter, Inc. Announces the Relocation of Its Corporate Headquarters in Baltimore 2
... RICHMOND, Va., Oct. 28 A leading authority on the ... a looming "caregiver crunch" impacting the ability of Americans to ... their loved ones. , On November 12, Dr. Dychtwald will ... coming "caregiver crunch" and the importance of long term care ...
... BLOOMINGTON, Minn., Oct. 28 The Child Neurology Foundation ... Spasms Awareness Week (October 11-17) that will go towards ... of epilepsy. , "Due to its rare nature, ... as it should be," said Lawrence Brown, M.D., Associate ...
... Biomedical Research Centre (BRC) for Mental Health at South ... of Psychiatry (IoP) , King,s College London (KCL) has ... support the development of the BRC,s Case Register Interactive ... research tool developed by the BRC,s cross-cutting Analytical Methodologies ...
... ... Administration (FDA) approval of its biologics license application (BLA) for the first 15 monoclonal antibodies ... entered into an exclusive agreement with the MED Alliance Group, Inc. (MAGI) to serve as ... ...
... Health & Hospital System is responding to the ... expanding its language access program to include approximately ... other locations throughout Parkland Memorial Hospital. The unique, ... leading interpretation and translation provider, are used to ...
... Morphotek®, Inc., a subsidiary of Eisai Inc., announced today ... Centocor Ortho Biotech Inc. for development and commercialization of ... many solid tumors. , Under the terms ... worldwide license for the development, manufacture and sale of ...
Cached Medicine News:Health News:Dr. Ken Dychtwald to Discuss Looming 'Caregiver Crunch' and the Importance of Proactive Long Term Care Planning 2Health News:Child Neurology Foundation Announces $30,000 Grant for Research Into Cause and Treatment of Infantile Spasms 2Health News:Child Neurology Foundation Announces $30,000 Grant for Research Into Cause and Treatment of Infantile Spasms 3Health News:Quotient Biodiagnostics Signs MED Alliance Group, Inc. as Exclusive Distributor in Midwest for Line of Transfusion Diagnostics 2Health News:Quotient Biodiagnostics Signs MED Alliance Group, Inc. as Exclusive Distributor in Midwest for Line of Transfusion Diagnostics 3Health News:Parkland Health & Hospital System Expands Language Access with Language Line(R) Phones in Every Patient Room 2Health News:Parkland Health & Hospital System Expands Language Access with Language Line(R) Phones in Every Patient Room 3Health News:Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody 2
(Date:9/1/2014)... , Sept. 1, 2014 ... report is available in its catalogue: ... 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... a new class of therapeutic agents, gaining increasing ... Generally addressed as the marriage of an antibody ...
(Date:8/30/2014)... , Aug. 30, 2014  Boston Scientific ... NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical ... trial investigating vagus nerve stimulation (VNS) for the ... Ph.D., Professor of Therapeutics and Cardiology and Director ... National de la Sante et de la Recherche ...
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... (KOLs) can be the difference between a product,s success ... effectively map and stratify KOL targets – and then ... the type of strong relationships upon which successful KOL ... savvy pharma companies have identified internal inconsistencies in their ...
Breaking Medicine Technology:Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Implementing a Strategic Thought Leader Management & Engagement System 2
... Dec. 21, 2010 Bellicum Pharmaceuticals, Inc. today announced ... will be used to prepare for Phase II trials ... resistant prostate cancer (mCRPC), and CaspaCIDe™, a cell therapy ... cell therapy (HSCT) setting. The new funding ...
... Dec. 21, 2010 The American Heart Journal ... Amorcyte, Inc.,s lead product candidate, AMR-001 for the treatment ...  Data demonstrated a significant relationship between cell dose and ... to prospectively define a dose of a purified and ...
Cached Medicine Technology:Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding 2Amorcyte Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients 2Amorcyte Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: